The U.S. Food and Drug Administration (FDA) has cleared Everest Medicines’ Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine. EVM14 is Everest’s first internally developed mRNA therapeutic vaccine to receive FDA IND approval, marking a significant milestone in the Company’s efforts to develop innovative mRNA therapeutics in oncology. EVM14 targets multiple tumor-associated antigens and is designed to treat various cancers. In preclinica...